Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
04:31pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
12:48pm, Thursday, 01'st Dec 2022
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
10:21am, Wednesday, 30'th Nov 2022 The Motley Fool
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
05:21am, Wednesday, 30'th Nov 2022
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.
7 Undervalued Biotech Stocks to Buy Before They Boom
08:30pm, Tuesday, 29'th Nov 2022
You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
The Smartest Stocks to Buy With $20 Right Now
10:21am, Wednesday, 16'th Nov 2022 The Motley Fool
You don't need a mountain of cash to begin building wealth on Wall Street.
The Smartest Stocks to Buy With $20 Right Now
05:21am, Wednesday, 16'th Nov 2022
You don't need a mountain of cash to begin building wealth on Wall Street.
2 No-Brainer Stocks to Buy Right Now for Less than $20
02:15pm, Saturday, 12'th Nov 2022 The Motley Fool
These stocks are still bargain-priced but benefit from long-term trends.
2 No-Brainer Stocks to Buy Right Now for Less than $20
09:15am, Saturday, 12'th Nov 2022
These stocks are still bargain-priced but benefit from long-term trends.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
04:05pm, Thursday, 10'th Nov 2022
ALAMEDA, Calif.--( BUSINESS WIRE )--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences
Here's Why This Growth Stock Is Already My 2022 Winner
02:53pm, Wednesday, 09'th Nov 2022 The Motley Fool
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Here's Why This Growth Stock Is Already My 2022 Winner
09:53am, Wednesday, 09'th Nov 2022
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Exelixis: Undervalued And Unloved
07:08am, Monday, 07'th Nov 2022
Today, we circle back on mid-cap oncology concern Exelixis, Inc. which just delivered another quarter of rock-solid results. Its blockbuster drug CABOMETYX continues to show good growth and the compan
What 4 Analyst Ratings Have To Say About Exelixis
07:16pm, Wednesday, 02'nd Nov 2022 Benzinga
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
1
0
0
Last 30D
0
1
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
03:23pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
